TRex Bio is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. The company focuses on restoring regulatory T cell (Treg) function to drive tissue repair and achieve durable disease remission. TRex Bio discovers drug candidates using its proprietary Deep Biology platform, which analyzes fresh human tissue from healthy and diseased donors to study tissue-specific Treg biology. Its lead product candidate is TRB-061, a TNFR2 agonist in clinical development for atopic dermatitis and alopecia areata. Its second candidate, TRB-071, is a CD30 agonist targeting inflammatory bowel disease. The company also collaborates with Eli Lilly to advance TRB-051 for lupus. TRex Bio operates a pre-commercial business model with no approved products. The company finances operations through equity offerings and pharmaceutical partnerships, where it licenses selected platform-derived targets in exchange for upfront payments, milestones, and royalties, while retaining and advancing its own wholly-owned pipeline toward independent development.